SEC Filing Summary
Filing identity: The supplied filing is for Foresight Acquisition Corp., not P3 Health Partners Inc. Investors should verify the company and filing identifier before relying on this summary.
Business Context and Reporting Period
Foresight Acquisition Corp. was incorporated on August 20, 2020 as a special purpose acquisition company (SPAC). It had no operating business as of December 31, 2020 and was formed to identify and complete an initial business combination. Its intended focus was technology-enabled consumer and consumer healthcare businesses, although the company retained broad industry flexibility.
The audited financial statements cover the period from inception on August 20, 2020 through December 31, 2020. The company had not commenced operations or generated operating revenue during the period.
Financial Metrics and Liquidity
| Metric | Period-end or period amount |
|---|---|
| Revenue | $0; no operating revenue was generated |
| Net loss | $2,286 for the inception-to-date period |
| Formation and operating costs | $2,286 |
| Cash at December 31, 2020 | $179,512 |
| Total assets | $394,960, including $215,448 of deferred offering costs |
| Total current liabilities | $372,246 |
| Related-party promissory notes | $275,000 outstanding at December 31, 2020 |
| Stockholders’ equity | $22,714 |
| Net cash used in operating activities | $0 |
| Net cash provided by financing activities | $179,512 |
| Debt | No long-term debt; related-party promissory notes were short-term and were repaid at the February 2021 IPO closing |
Following year-end, on February 12, 2021, the company completed an IPO of 31,625,000 units at $10.00 per unit, generating gross proceeds of $316.25 million. It also sold 832,500 private placement units for $8.325 million. Of the combined proceeds, $316.25 million was placed in a trust account. Transaction costs were $6.828 million, including $6.325 million of underwriting fees.
Management stated that approximately $305.2 million would initially be available for a business combination after the marketing fee, assuming no redemptions. The filing does not provide operating margins because the company had no operating revenue.
Material Changes Versus the Prior Comparable Period
- No prior comparable operating period is presented; the company was newly formed in August 2020.
- The principal change after December 31, 2020 was the February 2021 IPO and private placement, which substantially increased liquidity and funded the trust account.
- The company transitioned from sponsor-funded formation activities to a publicly financed SPAC seeking a business combination.
- The related-party promissory notes balance of $275,000 at year-end was repaid upon completion of the IPO.
Guidance, Outlook, Risks and Unusual Items
- The company expected no operating revenue until after completion of an initial business combination.
- The initial business combination was required to be completed by February 12, 2023, subject to any approved extension. Failure to complete a transaction would result in liquidation and redemption of public shares, while warrants would expire worthless.
- Public stockholders generally could redeem shares for their pro rata share of the trust account, initially anticipated at approximately $10.00 per share, subject to minimum net tangible asset and other transaction requirements.
- The company had no selected target, agreement or arrangement with a prospective target as of the filing.
- Material risks included failure to complete a transaction, limited funds outside the trust account, dilution from additional equity or debt financing, conflicts of interest involving sponsors and directors, creditor claims against the trust account, COVID-19-related transaction disruption, warrant dilution and potential Nasdaq delisting.
- The sponsor agreed to indemnify the trust account for certain third-party claims that could reduce the balance below $10.00 per public share, but the filing states that the sponsor was newly formed, its assets were believed to consist primarily of company securities, and its ability to satisfy the obligation had not been independently verified.
- Management disclosed that COVID-19 could negatively affect the company’s financial position, operations and target search, although the specific impact was not determinable.
- The company paid or expected to pay its sponsor $10,000 per month for office, administrative and support services beginning February 9, 2021, until the earlier of a business combination or liquidation.
- Management reported effective disclosure controls as of December 31, 2020. The filing did not include management’s assessment or an auditor attestation regarding internal control over financial reporting because of the applicable transition period for newly public companies.
Important Facts for Investors to Verify
- Confirm that this Foresight Acquisition Corp. filing, rather than a P3 Health Partners Inc. filing, is the intended document.
- Verify the post-year-end IPO, trust-account balance, underwriting costs and private placement terms in subsequent filings.
- Review whether and when Foresight completed an initial business combination and identify the resulting operating company.
- Assess redemption activity, sponsor ownership, potential dilution from founder shares, private placement securities and warrants.
- Review the trust-account protections, sponsor indemnification capacity and possible creditor or bankruptcy claims.
- Check any amendments extending the February 12, 2023 transaction deadline and any changes to redemption or warrant terms.